Nippon India Pharma Fund Direct Growth

Equity

Sectoral / Thematic

Very High

27-Oct-2023

₹ 374.60

Investment Returns (CAGR)

1 yr.
19.61

3 yr.
15.71

5 yr.
19.4

Since Inception.
15.1%

Fund Overview

Fund Size (Rs.)
5688 Cr

Exit Load
Exit load of 1% if redeemed within 1 month.

Scheme Type
Growth

ISIN
INF204K01I50

Expense Ratio
0.96%

Minimum SIP (Rs.)
100

Launch Date
31-Dec-2012

Fund House
Nippon India Mutual Fund

Investment Returns Calculator

Monthly SIP

Lump Sum

Monthly investment

₹10000

Time period

3yr

Expected Annual Return

10%

Your results

Total Value of your Investment:

Invested Amount

Est. Returns

Result will be displayed here

Check your eligible loan amount against mutual funds

Total Value of your mutual fund

₹

You are eligible for

₹

50,000

Minimum portfolio value: ₹50,000

Interest Rate: 10% *

Choose tenure

6 mon 12 mon 18 mon

24 mon

installment options

Balloon

₹

416

per month

EMI

₹

4395

per month

Apply For Loan

What is a loan against mutual funds?

With a Loan against Mutual Fund, you offer your MF units as collateral for the loan. The lender holds the Mutual Fund units as a security till you repay the loan amount. Your Mutual Funds will continue to earn returns, but you cannot sell them while you have pledged them to the lender.

You may borrow up to 50% of the value of your equity mutual fund schemes in your portfolio. The value of your mutual fund scheme is derived by multiplying the number of units by the scheme's NAV. The total value of all equity mutual fund schemes will be used to calculate your portfolio value.

Loan facility is provided by our NBFC partner

Apply For Loan

Check out related funds:

ICICI Prudential PSU Equity Fund Direct Growth

Equity

Sectoral / Thematic

Fund Size (Rs.)
1584 Cr

Expense Ratio
0.59%

3 yr. CAGR
NA

Risk level
Very High

ICICI Prudential PSU Equity Fund Direct IDCW

Equity

Sectoral / Thematic

Fund Size (Rs.)
1584 Cr

Expense Ratio
0.59%

3 yr. CAGR
NA

Risk level
Very High

Kotak Business Cycle Fund Direct Growth

Equity

Sectoral / Thematic

Fund Size (Rs.)
2527 Cr

Expense Ratio
0.3%

3 yr. CAGR
NA

Risk level
Very High

About Nippon India Pharma Fund Direct Growth

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. ;

Nippon India Pharma Fund Direct Growth

Equity

Sectoral / Thematic

Very High

27-Oct-2023

₹ 374.60

Fund Overview

Fund Size (Rs.)
5688 Cr

Benchmark Index
----

Scheme Type
Growth

ISIN
INF204K01I50

Expense Ratio
0.96%

Minimum SIP (Rs.)
100

Launch Date
31-Dec-2012

Fund House
Nippon India Mutual Fund

Exit Load
Exit load of 1% if redeemed within 1 month.

Investment Returns (CAGR)

1 yr. 19.61

3 yr. 15.71

5 yr. 19.4

Since Inception. 15.1%

Investment Returns Calculator

Monthly SIP

Lump Sum

Monthly investment

₹10000

Time period

3yr

Expected Annual Return

10%

Your results

Total Value of your Investment:

Invested Amount

Est. Returns

result_mweb will be displayed here

Check your eligible loan amount against your mutual funds.

Total Value of your mutual fund

₹

You are eligible for

₹

50,000

Minimum portfolio value: ₹50,000

Interest Rate: 10% *

Choose tenure

6 mon 12 mon 18 mon

24 mon

installment options

Balloon

₹

416

per month

EMI

₹

4395

per month

Apply For Loan

Loan facility is provided by our NBFC partner

What is a
loan against
mutual funds?

Apply now

Check out related funds:

ICICI Prudential PSU Equity Fund Direct Growth

Equity

Sectoral / Thematic

Fund Size (Rs.)
1584 Cr

Expense Ratio
0.59%

3 yr. CAGR
NA

Risk level
Very High

ICICI Prudential PSU Equity Fund Direct IDCW

Equity

Sectoral / Thematic

Fund Size (Rs.)
1584 Cr

Expense Ratio
0.59%

3 yr. CAGR
NA

Risk level
Very High

Kotak Business Cycle Fund Direct Growth

Equity

Sectoral / Thematic

Fund Size (Rs.)
2527 Cr

Expense Ratio
0.3%

3 yr. CAGR
NA

Risk level
Very High

About Nippon India Pharma Fund Direct Growth

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. ;